218 related articles for article (PubMed ID: 15290850)
1. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.
Koushik K; Dhanda DS; Cheruvu NP; Kompella UB
Pharm Res; 2004 Jul; 21(7):1119-26. PubMed ID: 15290850
[TBL] [Abstract][Full Text] [Related]
2. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
3. PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).
Gupta V; Davis M; Hope-Weeks LJ; Ahsan F
Pharm Res; 2011 Jul; 28(7):1733-49. PubMed ID: 21626061
[TBL] [Abstract][Full Text] [Related]
4. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs.
Patel B; Rashid J; Ahsan F
Eur J Pharm Sci; 2017 Jan; 96():560-570. PubMed ID: 27989858
[TBL] [Abstract][Full Text] [Related]
5. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.
Ungaro F; De Rosa G; Miro A; Quaglia F; La Rotonda MI
Eur J Pharm Sci; 2006 Aug; 28(5):423-32. PubMed ID: 16806857
[TBL] [Abstract][Full Text] [Related]
6. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Dhanda DS; Tyagi P; Mirvish SS; Kompella UB
J Control Release; 2013 Jun; 168(3):239-50. PubMed ID: 23562638
[TBL] [Abstract][Full Text] [Related]
7. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery.
Vega E; Egea MA; Calpena AC; Espina M; García ML
Int J Nanomedicine; 2012; 7():1357-71. PubMed ID: 22457594
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.
Patel B; Gupta N; Ahsan F
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):12-20. PubMed ID: 24286441
[TBL] [Abstract][Full Text] [Related]
9. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process.
Koushik K; Kompella UB
Pharm Res; 2004 Mar; 21(3):524-35. PubMed ID: 15070105
[TBL] [Abstract][Full Text] [Related]
10. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin.
Koushik KN; Bandi N; Kompella UB
Pharm Dev Technol; 2001 Nov; 6(4):595-606. PubMed ID: 11775960
[TBL] [Abstract][Full Text] [Related]
11. Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.
Gupta V; Ahsan F
Int J Pharm; 2011 Jul; 413(1-2):51-62. PubMed ID: 21530623
[TBL] [Abstract][Full Text] [Related]
12. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-beta-cyclodextrin system.
De Rosa G; Larobina D; Immacolata La Rotonda M; Musto P; Quaglia F; Ungaro F
J Control Release; 2005 Jan; 102(1):71-83. PubMed ID: 15653135
[TBL] [Abstract][Full Text] [Related]
13. NanoCipro encapsulation in monodisperse large porous PLGA microparticles.
Arnold MM; Gorman EM; Schieber LJ; Munson EJ; Berkland C
J Control Release; 2007 Aug; 121(1-2):100-9. PubMed ID: 17604870
[TBL] [Abstract][Full Text] [Related]
14. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
15. Large porous particles for pulmonary drug delivery.
Edwards DA; Hanes J; Caponetti G; Hrkach J; Ben-Jebria A; Eskew ML; Mintzes J; Deaver D; Lotan N; Langer R
Science; 1997 Jun; 276(5320):1868-71. PubMed ID: 9188534
[TBL] [Abstract][Full Text] [Related]
16. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
Patel B; Gupta V; Ahsan F
J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
[TBL] [Abstract][Full Text] [Related]
17. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy.
Vega E; Egea MA; Garduño-Ramírez ML; García ML; Sánchez E; Espina M; Calpena AC
Colloids Surf B Biointerfaces; 2013 Oct; 110():339-46. PubMed ID: 23743255
[TBL] [Abstract][Full Text] [Related]
18. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying.
Quaglia F; De Rosa G; Granata E; Ungaro F; Fattal E; Immacolata La Rotonda M
J Control Release; 2003 Jan; 86(2-3):267-78. PubMed ID: 12526823
[TBL] [Abstract][Full Text] [Related]
19. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
20. A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres.
Liu J; Meisner D; Kwong E; Wu XY; Johnston MR
Biomaterials; 2007 Jul; 28(21):3236-44. PubMed ID: 17434581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
